Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4822 participants.

Also called NCT01920711

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,822 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01920711
  • EudraCT 2013-001747-31
Other papers using this trial's data
  • Analysis of the PARAGON-HF Study Results Using Win Ratio Circulation. Heart failure, 2024-09 DOI, PubMed 39193709
  • Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial JACC. Heart failure, 2025-01 DOI, PubMed 39570234
  • Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction Circulation, 2020-09-29 DOI, PubMed 32845715
  • Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction The New England journal of medicine, 2019-10-24 DOI, PubMed 31475794
  • Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF European journal of heart failure, 2024-08 DOI, PubMed 38932589
  • Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Journal of the American College of Cardiology, 2019-12-10 DOI, PubMed 31806129, PMC13537700 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF Journal of the American College of Cardiology, 2020-08-04 DOI, PubMed 32731928
  • Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF Circulation, 2024-07-23 DOI, PubMed 38841854
  • Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction JACC. Heart failure, 2020-05 DOI, PubMed 32241619
  • Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial Circulation. Heart failure, 2021-04 DOI, PubMed 33866828
  • Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial European heart journal, 2025-07-01 DOI, PubMed 39873282, PMC12208775 PubMed links an erratum for this paper. Erratum: PMID 40705482 In the PMC Open Access subset under CC BY-NC.
  • Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF Journal of the American College of Cardiology, 2020-01-28 DOI, PubMed 31726194, PMC7983315 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Prognostic Significance of Nutritional Scores in Patients With Heart Failure: Insights From the PARAGON-HF Trial Journal of the American Heart Association, 2025-05-06 DOI, PubMed 40265602, PMC12184571 In the PMC Open Access subset under CC BY-NC-ND.
  • Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial Circulation. Heart failure, 2024-10 DOI, PubMed 39212045, PMC13000924 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction European heart journal, 2021-09-21 DOI, PubMed 34392331, PMC8455346 In the PMC Open Access subset under CC BY-NC.
  • Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction Journal of the American College of Cardiology, 2022-09-20 DOI, PubMed 36050227
  • Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction Journal of the American College of Cardiology, 2024-05-07 DOI, PubMed 38537919
  • Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trial European journal of heart failure, 2025-01 DOI, PubMed 39217577
  • Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan Journal of the American College of Cardiology, 2020-04-14 DOI, PubMed 32192799, PMC8109279 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Guatemala, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01920711. Randomized; double masking; primary purpose treatment. Start 2014-07-18 (actual); primary completion 2019-06-07 (actual). Results posted on 2020-09-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Acronym
PARAGON-HF
Intervention (Drug)
LCZ696
Intervention (Drug)
Valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01920711
Content hash
072d0d61d0ef63eb7943fba67129998d1b563cbc0c53ce2f4ce2b4c2ee8298ec